<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37158726</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>15</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Latent Tuberculosis Infection and Associated Factors in Patients with Systemic Lupus Erythematosus: a Multicenter, Cross-Sectional Study.</ArticleTitle><Pagination><StartPage>e0084823</StartPage><MedlinePgn>e0084823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00848-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.00848-23</ELocationID><Abstract><AbstractText>The objectives of this study were to screen for latent tuberculosis infection (LTBI) among patients with systemic lupus erythematosus (SLE) using the T-SPOT.TB assay and to identify factors affecting the assay results. SLE patients were enrolled from 13 tertiary hospitals in eastern, central, and western China from September 2014 to March 2016 and were screened using the T-SPOT.TB assay to detect LTBI. Basic information about the subjects was collected, including gender, age, body mass index (BMI), course of disease, evidence of previous tuberculosis, Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, and the use of glucocorticoids and immunosuppressants. Univariate analysis and multivariable logistic regression were performed to identify factors affecting the results of the T-SPOT.TB assay. In all, 2,229 SLE patients were screened using the T-SPOT.TB assay, of whom 334 patients tested positive, yielding a positivity rate of 15% (95% confidence interval [CI], 13.5% to 16.5%). The positivity rate was higher in male than female patients and had an increasing trend with age. Multivariable logistic regression analysis showed that patients over 40 (odds ratio [OR], 1.65; 95% CI, 1.29 to 2.10) and with evidence of previous tuberculosis (OR, 4.43; 95% CI, 2.81 to 6.99) were more likely to have positive T-SPOT.TB results, while patients with a SLEDAI-2K score of &#x2265;10 (OR, 0.61; 95% CI, 0.43 to 0.88), a glucocorticoid dose of &#x2265;60&#x2009;mg/d (OR, 0.62; 95% CI, 0.39 to 0.98), leflunomide (LEF) treatment (OR, 0.51; 95% CI, 0.29 to 0.88), or tacrolimus (FK506) treatment (OR, 0.40; 95% CI, 0.16 to 1.00) were more likely to have negative T-SPOT.TB results. The frequencies of CFP-10-specific gamma interferon (IFN-&#x3b3;)-secreting T cells were significantly lower in SLE patients with severe disease activity or high-dose glucocorticoids (<i>P</i>&#x2009;&lt;&#x2009;0.05). The positivity rate of the T-SPOT.TB assay was 15% among SLE patients. Severe, active SLE disease and the use of high-dose glucocorticoids and some types of immunosuppressants are likely to result in negative T-SPOT.TB results. For SLE patients with the above conditions, diagnosing LTBI based on a positive T-SPOT.TB result may lead to underestimation of the prevalence. <b>IMPORTANCE</b> The burden of tuberculosis and systemic lupus erythematosus in China ranks among the top three in the world. Therefore, active screening for LTBI and preventive intervention in SLE patients are of great significance in China. In view of the lack of relevant data in a large sample, we conducted a multicenter, cross-sectional study using T-SPOT.TB as a screening method for LTBI, to investigate the prevalence of LTBI and analyze the factors affecting the results of the T-SPOT.TB assay in SLE patients. Our study showed that the overall positivity rate of the T-SPOT.TB assay in SLE patients was 15.0%, which was lower than the estimated LTBI prevalence in the general population in China (~20%). For SLE patients with severe, active disease, high-dose glucocorticoids, and some types of immunosuppressants, a diagnosis of LTBI based on only positive T-SPOT.TB results may lead to underestimation of the prevalence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Lifan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, International Epidemiology Network, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>Yanan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yueqiu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fengchun</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shengyun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Huaxiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongbin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhiyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Miaojia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Wencheng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Tianjin First Central Hospital, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Huaxiang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Qilu Hospital of Shandong University, Ji'nan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0008-5182-4233</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology Unit, International Epidemiology Network, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-PUMCH-C-013</GrantID><Agency>National High Level Hospital Clinical Research Funding</Agency><Country/></Grant><Grant><GrantID>2014ZX10003003</GrantID><Agency>National Science and Technology Major Project ()</Agency><Country/></Grant><Grant><GrantID>2017ZX10201302-003</GrantID><Agency>National Science and Technology Major Project ()</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055985" MajorTopicYN="Y">Latent Tuberculosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014374" MajorTopicYN="N">Tuberculin Test</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">T-SPOT.TB</Keyword><Keyword MajorTopicYN="N">latent tuberculosis infection</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37158726</ArticleId><ArticleId IdType="pmc">PMC10269486</ArticleId><ArticleId IdType="doi">10.1128/spectrum.00848-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global tuberculosis report. 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240037021.</Citation></Reference><Reference><Citation>Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, Svenungsson E, Peterson J, Clarke AE, Ramsey-Goldman R. 2021. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17:515&#x2013;532. doi:10.1038/s41584-021-00668-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00668-1</ArticleId><ArticleId IdType="pmc">PMC8982275</ArticleId><ArticleId IdType="pubmed">34345022</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group. 2020. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 59:172&#x2013;185. (In Chinese.) doi:10.3760/cma.j.issn.0578-1426.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0578-1426.2020.03.002</ArticleId><ArticleId IdType="pubmed">32146743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention, Chinese Academy of Sciences. 2022. Expert consensus on the estimation of the national burden on latent tuberculosis infection. Zhongguo Fang Lao Za Zhi 44:4&#x2013;8.</Citation></Reference><Reference><Citation>Pego-Reigosa JM, Nicholson L, Pooley N, Langham S, Embleton N, Marjenberg Z, Barut V, Desta B, Wang X, Langham J, Hammond ER. 2021. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford) 60:60&#x2013;72. doi:10.1093/rheumatology/keaa478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa478</ArticleId><ArticleId IdType="pmc">PMC7785308</ArticleId><ArticleId IdType="pubmed">33099651</ArticleId></ArticleIdList></Reference><Reference><Citation>Anton C, Machado FD, Ramirez JMA, Bernardi RM, Palominos PE, Brenol CV, Mello FCdQ, Silva DR. 2019. Latent tuberculosis infection in patients with rheumatic diseases. J Bras Pneumol 45:e20190023. doi:10.1590/1806-3713/e20190023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1806-3713/e20190023</ArticleId><ArticleId IdType="pmc">PMC6733747</ArticleId><ArticleId IdType="pubmed">31038654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Yang Z, Bao X, Ma H, Ge Q, Zhang Y, Cao Q, Gao M, Liu X. 2022. Comparison of diagnostic accuracy of QuantiFERON-TB Gold Plus and T-SPOT.TB in the diagnosis of active tuberculosis in febrile patients. J Evid Based Med 15:97&#x2013;105. doi:10.1111/jebm.12477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jebm.12477</ArticleId><ArticleId IdType="pmc">PMC9540107</ArticleId><ArticleId IdType="pubmed">35762517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QW, Chen JQ, Zhong WQ, Wu Y, Zhao Y, Deng G. 2022. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases. Zhonghua Nei Ke Za Zhi 61:1300&#x2013;1309. (In Chinese.) doi:10.3760/cma.j.cn112138-20220629-00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn112138-20220629-00485</ArticleId><ArticleId IdType="pubmed">36456509</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin V, Akici A, Isli F, Aksoy M, Aydin M, Gursoz H. 2019. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: a nationwide cohort study. J Clin Pharm Ther 44:553&#x2013;560. doi:10.1111/jcpt.12814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.12814</ArticleId><ArticleId IdType="pubmed">30763469</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyo J, Cho S-K, Kim D, Sung Y-K. 2018. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases. Korean J Intern Med 33:1241&#x2013;1251. doi:10.3904/kjim.2016.222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2016.222</ArticleId><ArticleId IdType="pmc">PMC6234384</ArticleId><ArticleId IdType="pubmed">29277097</ArticleId></ArticleIdList></Reference><Reference><Citation>Technical Guidance Group of the Fifth National TB Epidemiological Survey, Office of the Fifth National TB Epidemiological Survey. 2012. The fifth national tuberculosis epidemiological survey in 2010. Zhongguo Fang Lao Za Zhi 34:485&#x2013;508.</Citation></Reference><Reference><Citation>Xiao X, Da G, Xie X, Liu X, Zhang L, Zhou B, Li H, Li P, Yang H, Chen H, Fei Y, Tsokos GC, Zhao L, Zhang X. 2021. Tuberculosis in patients with systemic lupus erythematosus-a 37-year longitudinal survey-based study. J Intern Med 290:101&#x2013;115. doi:10.1111/joim.13218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13218</ArticleId><ArticleId IdType="pubmed">33259665</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Liu Y, Wang W, Zhang Y, Liu K, Chen S-H, Chen B. 2022. Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: a systematic review and meta-analysis. Front Immunol 13:938406. doi:10.3389/fimmu.2022.938406.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.938406</ArticleId><ArticleId IdType="pmc">PMC9355093</ArticleId><ArticleId IdType="pubmed">35935948</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes CMF, Terreri MT, Moraes-Pinto MI, Pinheiro MM. 2021. Performance of 4 methods for screening of latent tuberculosis infection in patients with chronic inflammatory arthritis under TNF&#x3b1; inhibitors: a 24-month prospective study. Adv Rheumatol 61:71. doi:10.1186/s42358-021-00226-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-021-00226-z</ArticleId><ArticleId IdType="pubmed">34838126</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xed;nguez S, Latorre I, Mateo L, Lacoma A, Diaz J, Oliv&#xe9; A, Dom&#xed;nguez J. 2012. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 31:785&#x2013;794. doi:10.1007/s10067-012-1938-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-1938-z</ArticleId><ArticleId IdType="pubmed">22271230</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E. 2011. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 18:2102&#x2013;2108. doi:10.1128/CVI.05299-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05299-11</ArticleId><ArticleId IdType="pmc">PMC3232699</ArticleId><ArticleId IdType="pubmed">21994356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G, Luo Q, Luo S, Teng Z, Ji Z, Yang J, Wang F, Wen S, Ding Z, Li L, Chen T, Abi M-E, Jian M, Luo L, Liu A, Bao F. 2020. Interferon-&#x3b3; release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis 20:1457&#x2013;1469. doi:10.1016/S1473-3099(20)30276-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30276-0</ArticleId><ArticleId IdType="pubmed">32673595</ArticleId></ArticleIdList></Reference><Reference><Citation>Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, Lange C, Losi M, Markova R, Migliori GB, Nienhaus A, Ruhwald M, Wagner D, Zellweger JP, Huitric E, Sandgren A, Manissero D. 2011. Interferon-&#x3b3; release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:88&#x2013;99. doi:10.1183/09031936.00115110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00115110</ArticleId><ArticleId IdType="pubmed">21030451</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Lu W, Bai L, Wang X, Xu J, Catanzaro A, C&#xe1;rdenas V, Li X, Yang Y, Du J, Sui H, Xia Y, Li M, Feng B, Li Z, Xin H, Zhao R, Liu J, Pan S, Shen F, He J, Yang S, Si H, Wang Y, Xu Z, Tan Y, Chen T, Xu W, Peng H, Wang Z, Zhu T, Zhou F, Liu H, Zhao Y, Cheng S, Jin Q, LATENTTB-NSTM Study Team . 2015. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis 15:310&#x2013;319. doi:10.1016/S1473-3099(14)71085-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(14)71085-0</ArticleId><ArticleId IdType="pubmed">25681063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L, Zhang H, Hu M-G, Xu C-D, Xia Y-Y, Li T, Chen W, He Y-J, Cao X-F, Xin H-N, Zhang H-R, Zhao Y-L, Wang J-F, Cheng S-M, Jin Q, Liu J-J. 2022. Estimation of the national burden on latent tuberculosis infection based a multi-center epidemiological survey and the space statistics model. Zhongguo Fang Lao Za Zhi 44:54.</Citation></Reference><Reference><Citation>Liu S, Wu M, A E, Wu S, Geng S, Li Z, Li M, Li L, Pang Y, Kang W, Tang S. 2021. Factors associated with differential T cell responses to antigens ESAT-6 and CFP-10 in pulmonary tuberculosis patients. Medicine (Baltimore) 100:e24615. doi:10.1097/MD.0000000000024615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000024615</ArticleId><ArticleId IdType="pmc">PMC7909155</ArticleId><ArticleId IdType="pubmed">33663071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigdel KR, Duan L, Wang Y, Hu W, Wang N, Sun Q, Liu Q, Liu X, Hou X, Cheng A, Shi G, Zhang Y. 2016. Serum cytokines Th1, Th2, and Th17 expression profiling in active lupus nephritis-IV: from a southern Chinese Han population. Mediators Inflamm 2016:4927530. doi:10.1155/2016/4927530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4927530</ArticleId><ArticleId IdType="pmc">PMC5055982</ArticleId><ArticleId IdType="pubmed">27738386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SS, Park ES, Shim JS, Ha S-J, Kim BS, Jung SM, Lee S-W, Park Y-B, Song JJ. 2017. Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. Arthritis Res Ther 19:193. doi:10.1186/s13075-017-1404-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1404-z</ArticleId><ArticleId IdType="pmc">PMC5574096</ArticleId><ArticleId IdType="pubmed">28841837</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;lard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Lassen I, Ravn P. 2011. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17:2340&#x2013;2349. doi:10.1002/ibd.21605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.21605</ArticleId><ArticleId IdType="pubmed">21319275</ArticleId></ArticleIdList></Reference><Reference><Citation>Arenas Miras MDM, Hidalgo-Tenorio C, Jimenez-Gamiz P, Jim&#xe9;nez-Alonso J. 2014. Diagnosis of latent tuberculosis in patients with systemic lupus erythematosus: T.SPOT.TB versus tuberculin skin test. Biomed Res Int 2014:291031. doi:10.1155/2014/291031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/291031</ArticleId><ArticleId IdType="pmc">PMC4058455</ArticleId><ArticleId IdType="pubmed">25009813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SC, Lai YY, Huang MC, Tsai CS, Wang JL. 2018. Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. Lupus 27:1819&#x2013;1827. doi:10.1177/0961203318792352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318792352</ArticleId><ArticleId IdType="pubmed">30103646</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SH, Gao Q, Tsoi KKF, Wu WKK, Tam L-S, Lee N, Chan FKL, Wu JCY, Sung JJY, Ng SC. 2016. Effect of immunosuppressive therapy on interferon &#x3b3; release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 71:64&#x2013;72. doi:10.1136/thoraxjnl-2015-207811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2015-207811</ArticleId><ArticleId IdType="pubmed">26659461</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamri RD, Elmeligy MA, Albalawi GA, Alquayr SM, Alsubhi SS, El-Ghaiesh SH. 2021. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: a comprehensive review. Int Immunopharmacol 93:107398. doi:10.1016/j.intimp.2021.107398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107398</ArticleId><ArticleId IdType="pmc">PMC7869628</ArticleId><ArticleId IdType="pubmed">33571819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundbaum JK, Arkema EV, Bruchfeld J, Jonsson J, Askling J, Baecklund E. 2021. Tuberculosis in biologic-naive patients with rheumatoid arthritis: risk factors and tuberculosis characteristics. J Rheumatol 48:1243&#x2013;1250. doi:10.3899/jrheum.201251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.201251</ArticleId><ArticleId IdType="pubmed">33795331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC. 2017. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 31:429&#x2013;438. doi:10.1016/j.berh.2017.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2017.09.010</ArticleId><ArticleId IdType="pubmed">29224682</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting S-W, Ting S-Y, Lin Y-S, Lin M-S, Kuo G. 2021. Association between different systemic therapies and the risk of tuberculosis in psoriasis patients: a population-based study. Int J Clin Pract 75:e15006. doi:10.1111/ijcp.15006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.15006</ArticleId><ArticleId IdType="pubmed">34773345</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Zhang L, Zhang F, Zeng X, Zhao Y, Wang Q, Liu S, Zuo X, Zhang Z, Wu H, Chen S, Li H, Zhu P, Wu L, Qi W, Liu Y, Zhang M, Liu H, Xu D, Zheng W, Zhang Y, Shi X, Han L, Zhou Y, Zhao Y, Wang W, Li T, Tie N, Zhang K, Luo C, Gong B, Zhao Y, Lv C, Song L, Wu Q, Fei Y, Zhang L, Luo H, Sun J, Xue J, Gu L, Wang J, Han Q, Yimaity K, Zhou J, Zhao L, Bian S, Qi W, Li Y, Zhu Y, et al.. 2021. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. Emerg Microbes Infect 10:2303&#x2013;2312. doi:10.1080/22221751.2021.2004864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2004864</ArticleId><ArticleId IdType="pmc">PMC8654396</ArticleId><ArticleId IdType="pubmed">34753408</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>